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Snapshot
Innovative mucosal vaccines for 
respiratory tract infectionsProducts
Mimopath® vaccine platformTechnology
Groningen (NL) & Rockville (USA)Based in
MedSciences, BioGeneration, NV-NOMPrivately Held
14 partners in US, Asia and EUPartners
Slide 2
~$16M from equity, credits & grantsFunding
20 FTEEmployees
Our Business
Mucosis is leveraging its Mimopath®
platform to revolutionize vaccination by 
developing novel mucosal vaccines that 
provide optimal protection in the 
mucosa, the site where >90% of 
pathogens enter the human body
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Mucosis’ innovative  vaccine
platform technology
Systemic immune response primarily
Complex adjuvant technologies 
Poor delivery methods Current 
limitations 
in 
vaccine
development
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Natural, balanced immune response: 
systemic and in the mucosa
Straightforward, with well-understood 
mode of action
Delivery through natural route (mucosa)
Mimopath®
vaccine
technology 
+ +BLP BLP
Ag Ag-Protan
Mimopath®: 
a versatile vaccine technology platform
Mixed Bound
BLP BLP
Innovative & differentiated vaccines:
• Robust systemic and mucosal responses
• Multiple routes of administration
• Suited for complex antigens
e.g. FluGEM® e.g. PneuGEM® 
SynGEM®
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BLP BLP
Mimopath®: 
a versatile vaccine technology platform
Mixed Bound
Nearly any antigen Any peptide or protein
(> 50 done in house)
– Viral, bacterial, parasitic
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• No size limitation
• Including complex glycosylated 
multimeric proteins
• Potentially also tumor and 
allergy antigens
– Multiple production platforms
• Bacterial (e.g. E. coli)
• Mammalian (e.g. CHO)
• Insect (e.g. S2)
• Yeast (e.g. Pichia)
Binding of Ag-Protan is easy 1 step process
A B
wild-type Lactococcus lactis
PGN
acid treatment
&
washes with
SP Antigen Protan
P
introduce Ag-Protan
in expression system
e.g. 
bacteria
eukaryotic cells
overexpression
BLP
C
pMUC155
5076 bps
1000
20003000
4000
5000
P
T
Ag-Protan
buffer to remove
acid and 
breakdown 
products
BLP
PGN
removal of
producer cells
BLP-Ag
vaccineAg-Protan fusion
add & mix
mixing results in
instant & strong
non-covalent binding
washes with buffer
BLP-Ag
GEM
BLP
Slide 7
pMUC1 55
5076 bps
1000
20003000
4000
5000
P
T
A g-Protan
Robust BLP manufacturing process
cGMP Manufacturing process:  
• Fermentation of L. lactis according to 
standard procedures
• Concentrate and wash with WFI
• Acid treatment at elevated Temp
• Concentrate and wash with PBS
• Final formulation in PBS
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BLP bulk material stability:  
• GLP bulk material stability study since Feb 2009
• cGMP bulk material stability study since Nov 2009
• Storage conditions: T=5oC and T=25oC
• Material is stable at both storage Temps
Large scale cGMP manufacturing feasible
Mimopath® is safe and well tolerated in man
Mucosal administration: 
- no local side effects
- toxin-free (no LPS)
- no recombinant DNA
BLPs derived from Lactococcus lactis, 
a safe bacterium used for food production 
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- no systemic side effects
- excellent safety & tolerability
confirmed in man
- non-living (no dissemination)
- qualified by FDA as G.R.A.S.
How does it
work?
CONFIDENTIALSlide 10
Addressing innate immunity is key
Stimulation 
&
Uptake 
Activation 
Migration 
Resting innate
Activated innate 
immune cells
TLR
BLP
immune cells Priming adaptive 
immune response
CD4+ T cells
help
B-cells  
CD8+ T-cells
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BLPs act through TLR2
T- and B-cells
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BLPs act through TLR2
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Mimopath® suitable for repeated vaccination
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αB-IgG response of BLP-B vaccine after prior intranasal
immunization with PBS or BLP-A vaccine
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Mimopath®
Proof of Concept
CONFIDENTIALSlide 18
Rationale for influenza (FluGEM ® program) as 
proof-of-concept model for Mimopath®
• Well-established correlates of protection
– Early assessment of potency of the platform technology in 
human trials (e.g. Hemagglutination titer > 40)
• Challenge models in animals readily available
– Allows for assessment of potency and efficacy of the vaccines
• Wide range of reagents available
– Characterisation of systemic responses
– Assessment of mucosal responses
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Mimopath® provides improved and lasting 
systemic immune response
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Immune response is well balanced Th1/ Th2
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Mimopath® elicits robust local and distant 
mucosal immunity
Distant (vagina)Local (Nose)
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PBS         HA      FluGEM®PBS        HA       FluGEM
®
Mimopath® provides superior protection &
cross protection
Disease score
Weight development and survival after PR8 challengeTiters in lung 5 days post PR8 challenge
Viral replication
100%
100%
100%
85%
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*Heterologous challenge
0%
*
*
0%0%
PBS FluGEM
PR8
IN
FluGEM*
NC
IN
HA PR8
IM
HA NC*
IM
0%
De Haan et al. (2012) Vaccine: accepted
Mimopath® elicits improved systemic & local
α-flu immune responses in healthy volunteers
HI titers
Day 0
nasal SIgA
Day 0 21 42
IN vaccinations
Blood sampling
Nasal washes
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Healthy adults (n=15) were vaccinated intranasally at d=0 and d=21 
3 weeks post each vaccination, HI titers (A/California/7/2009) 
and  nasal IgA were determined
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+                    +         TIV (15 µg HA/strain)
Mimopath® elicits an improved α-flu
CMI responses in healthy volunteers
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Mimopath® conclusions 
Superior SIgA titersMucosal response
Mimopath ® technology validated in manProof of concept
Safe and well toleratedSafety
Superior reduction of viral load & improved 
cross protection in relevant animal modelsProtection
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Balanced and lasting immunitySystemic response
Mimopath®
Display of complex multimeric
CONFIDENTIALSlide 27
antigens on BLPs
Proof of Concept
Rational for use of multimeric antigens
• Many important (viral) surface antigens are 
multimeric membrane glycoproteins
• Native multimeric Ags elicit most effective 
immune responses*
*Grundner et al. Virology 331 [2005] 33–46
Wei et al. J. Virol. 82 [2008] 6200-6208
Bosch et al. J. Virol. 84 [2010] 10366-10374 Slide 28
Proof of Concept: Influenza HA
N- -C
TM  CD
HA
N- -C
MD
HAtri
Protan
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heat heat
HAtri HAmonMedium Cell lysate
HAtri
A/Cal/7/2009 
• Trimeric HA protein 
from subtype A 
H1N1/Cal/7/2009
• Production on HEK293 
cells
HAtri has high affinity for BLPs
Mix and wash BLPHAtri
Medium+HCP
Medium BLP
Anti-A/Cal/7/2009 Ab
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HAtri
Concentration
factor
+ - Conc. medium
BLPs only
A/Cal/7/2009 HAtri
bound to BLPs
LightFluorescence
HAtri displayed on BLP is functional
ery BLP-HA
mon1 2 3BLP-HAtri
Virus
Slide 31
agglutinationagglutination
HAtri displayed on BLP is stable
Biological activity (HAU)HAtri bound to BLP
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HAtri displayed on BLP is highly immunogenic
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• Replacement of transmembrane domain by 
heterologous multimerization domain feasible
• Plug & play cassette available
• Multimeric Protan fusions efficiently bind to BLPs
Display of complex multimeric antigens:
conclusions
• Displayed proteins are functional, stable &  
immunogenic
• Applicable to multiple disease targets 
(Influenza, RSV, HIV, Herpes, SARS etc.)
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SynGEM®
Lead product
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Medical need 
• severe respiratory disease in children and elderly
• annually 64 million infections
• mortality 160,000 (in elderly as severe as Influenza)
• 18,000 to 75,000 hospitalizations (children, USA) 
Respiratory Syncitial Virus
Vaccine failure
- formaldehyde inactivated, alum adjuvanted vaccine (FI-RSV)
- enhanced disease in children upon natural infection
- cause: no neutralizing Ab
> response skewed towards Th2
> formaldehyde inactivation modification of (neutralizing) epitopes
> lack of affinity maturation (poor TLR stimulation)=low-avidity Ab
No registered vaccine available
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• Native (trimeric) F antigens bound to BLPs:
– Native F antigens elicit most effective immune responses*
• BLPs induce protection at the port of entry for RSV infection:
– Elicit robust mucosal immunity in respiratory tract
– Demonstrated in preclinical and clinical Mimopath®  POC program
• BLPs induce protection against RSV disease:
– Elicit potent humoral immune responses
Rationale for SynGEM®
– Importance of humoral immune responses demonstrated by the success of 
antibody-based therapy in reducing RSV-associated hospitalizations in high-risk 
infants
• BLPs prevent enhanced disease:
– Th1-biased responses demonstrated in preclinical Mimopath® POC program
– Contrasts with Th2-biased responses associated with enhanced disease 
observed with formalin-inactivated RSV vaccine
• BLPs provide safety advantages:
– Safe and well tolerated in man
– Non-living, non-replicating, and GRAS component
*Grundner et al. Virology 331 [2005] 33–46
Wei et al. J. Virol. 82 [2008] 6200-6208
Bosch et al. J. Virol. 84 [2010] 10366-10374 Slide 37
SynGEM ® characteristics
SynGEM® Intranasal
BLP
Synagis-like immune response Multimeric F-protein vaccine
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Sources: http://www.uct.ac.za/depts/mmi/stannard/syncytia.html
Swanson et al. 2011. PNAS 108:9619-9624.
Stabilized (trimeric) F antigen
BLPs displaying antigen as particle
BLP
N- -C
TM  CD
F
N- -C
MD
Ftri
Protan
Synagis Ab • Trimeric F(usion)    
SynGEM® displays stable trimeric F
Cleavage site
1  2
SynGEM®
Ftri
BLP
SynGEM ® 
BLP
protein from subtype A
• Production on 
HEK, CHO or insect 
cells
• Stable display of F on 
BLPs
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mice
F F F F F F F F
Transfer non-bound Synagis
Detect
Synagis
F F F F F F F F
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Slide 42Experiments performed at Sigmovir, USA
SynGEM® elicits protective responses
cotton rats
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* The control group which received IM administration with FI-RSV followed by an RSV challenge showed
enhanced disease as expected
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SynGEM® conclusions
RSV Ftri is bound in native conformation
& recognized by Synagis®
Display of RSV Ftri
on BLPs
SynGEM® induces Synagis-like Immunogenicity
neutralizing antibodies in mice
Protection
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SynGEM® does not induce enhanced 
diseaseSafety
SynGEM® provides protection in the 
cotton rat challenge model
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